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Abstract
Purpose To investigate the clinical utility of molecular breast imaging (MBI) in patients with proven invasive breast cancer 
scheduled for breast-conserving surgery (BCS).
Methods Following approval by the institutional review board and written informed consent, records of patients with newly 
diagnosed breast cancer scheduled for BCS who had undergone MBI for local staging in the period from March 2012 till 
December 2014 were retrospectively reviewed.
Results A total of 287 women (aged 30–88 years) were evaluated. MBI showed T stage migration in 26 patients (9%), with 
frequent detection of in situ carcinoma around the tumor. Surgical management was adjusted in 14 of these patients (54%). 
In 17 of 287 patients (6%), MBI revealed 21 proven additional lesions in the ipsilateral, contralateral breast or both. In 18 
of these additional foci (86%), detected in 15 patients, malignancy was found. Thirteen of these 15 patients had ipsilateral 
cancer and 2 patients bilateral malignancy. In total, MBI revealed a larger tumor extent, additional tumor foci or both in 40 
patients (14%), leading to treatment adjustment in 25 patients (9%).
Conclusion MBI seems to be a useful imaging modality with a high predictive value in revealing ipsilateral and bilateral 
disease not visualized by mammography and ultrasound. It may play an important role in delineating the extent of the index 
lesion during preoperative planning. Incorporation of MBI in the clinical work-up as an adjunct modality to mammography 
and ultrasound may lead to better selection of patients who could benefit from BCS.
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Introduction
Invasive breast cancer is the most common cancer among 
women, with an incidence of 14.479 new cases in 2016 
in The Netherlands [1] and 1.67 million new cancer cases 
diagnosed in 2012 worldwide [2].
In the last decades, breast-conserving surgery (BCS), 
also called lumpectomy, has gained importance due to 
the possibility to remove the tumor preserving the natural 
shape of the breast [3]. BCS is contraindicated in small 
breasts with large primary tumors and in case of multi-
centric tumors [3, 4]. Therefore, accurate definition of the 
extent of the primary tumor and exclusion of additional 
foci of cancer (multifocal, multicentric and contralateral 
breast cancer) is important in order to conduct the appro-
priate surgical treatment. Currently, magnetic resonance 
imaging (MRI) and molecular breast imaging (MBI) have 
been indicated to assess tumor extent and multifocal, mul-
ticentric and contralateral disease in adjunction to mam-
mography (MG) and ultrasonography (US) [5, 6]. MBI 
is a functional imaging technique consisting of a breast-
dedicated gamma camera equipped with a small field-
of-view (FOV) single- or dual-head detector, producing 
high-resolution images corresponding to the standard pro-
jections used in MG [7–11]. In MBI, tumor-seeking radi-
opharmaceuticals like 99mTc-sestamibi are used. Uptake of 
this tracer into tumor cells is based on increased vascular-
ity and high mitochondrial density [12–14]. Recently, a 
low-dose protocol with an injected dose of 260–500 MBq 
99mTc-sestamibi has been introduced using a single-head 
MBI device [15, 16]. Dual-head MBI devices allow even 
lower injected doses varying from 150 to 300 MBq of 
99mTc-sestamibi [11, 17]. This leads to both reduction 
of absorbed dose and effective dose to the breast [18]. 
Compared to MRI, MBI is easy to interpret, is associated 
with low costs and is not contraindicated in patients with 
claustrophobia, overweight, implanted devices and renal 
insufficiency.
The purpose of this study was to investigate the clinical 
utility of MBI in adjunction to MG and US for delineation 
of the extent of the index lesion and to rule out additional 




The institutional review board approved this retrospective 
study and informed consent was obtained from all patients. 
Patients were included if they fulfilled the following cri-
teria: (a) presence of histopathologically proven invasive 
breast cancer; (b) after conventional clinical work-up 
(including 2D MG, Siemens Inspiration Mammomat, and 
2D US, Philips Affiniti 70 G Linear transducer L 12-5) the 
patient was scheduled for BCS; (c) the patient had under-
gone pretreatment MBI for assessment of tumor extent and 
presence of multifocal or multicentric disease; (d) com-
plete individual data were available concerning clinical 
work-up, imaging, surgery and histopathology.
MBI acquisition
MBI imaging was performed using a dedicated device 
equipped with a single detector system also known as 
breast-specific gamma imaging (BSGI; Dilon 6800, Dilon 
Diagnostics, Newport News, Virginia, U.S.A.). Images were 
acquired with the patient in seated position and with the 
breast in light compression. At our institution, we used a 
relative low-dose protocol (600 MBq) in comparison with 
the most published articles (740–1110 MBq) [7–9]. As men-
tioned earlier, recent studies showed that it seems possible 
to use even lower injected doses with BSGI [15, 16]. Each 
patient received an injection of approximately 600 MBq of 
99mTc-sestamibi into an antecubital vein contralateral to the 
breast lesion. Approximately 5–10 min after the injection, 
craniocaudal (CC) and mediolateral oblique (MLO) planar 
images were obtained for each breast, comparable with those 
of MG. The acquisition time for each image was 8–10 min, 
giving a total acquisition time of approximately 40 min per 
study. If relevant, additional planar images (lateromedial or 
mediolateral view, anteroposterior view (axilla) or axillary 
craniocaudal view) were acquired from the ipsilateral breast.
MBI image analysis
All MBI images were evaluated by two nuclear medicine 
physicians of our institute (L.M.P.A-B and F.S.) and were 
directly compared with the most recent MG following the 
functional Breast Imaging Reporting and Data System (BI-
RADS) classification [6, 19].
The size of the index lesion was calculated by measuring 
the maximum diameter (mm) of the pathological uptake on 
the MBI images (MBI T stage). In case of more than one 
lesion, the maximum diameter of the largest tumor was used. 
Index lesion size detected on MBI was compared with the 
lesion size obtained with MG and US (MORPHOLOGICAL T 
stage).
MBI-detected abnormalities were considered to be addi-
tional tumor lesions when they were suspicious on MBI (BI-
RADS 4 or 5) and occult on MG and initially not picked up on 
US. At our institute, US is used to characterize a palpable mass 
or to find a correlate for a mammographical lesion. According 
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to this criterion, the radiologist performed US of a sole lesion 
and not of a quadrant of the breast nor the whole breast. The 
additional breast lesions were classified as follows: (1) multi-
focal lesions when located in the same quadrant of the breast 
as the index tumor; (2) multicentric lesions when located in a 
different quadrant of the breast compared to the index tumor; 
and (3) contralateral lesions when located in the contralateral 
breast. The size of each additional lesion was measured on 
MBI corresponding to the maximum diameter (mm) of the 
pathological uptake. Histopathology was obtained from all 
additional MBI lesions after incisional needle-biopsy or sur-
gical excision. The biopsy was performed using US-guided 
biopsy when the lesion was visible on targeted US. In more 
detail, after performing MBI and finding an additional suspi-
cious lesion, the patient returned to the radiology department 
to undergo targeted US. In most cases, the additional detected 
lesion was previously not picked up during diagnostic work-
up, since no routine whole breast screening US was performed. 
Targeted US was performed directly after MBI in case of an 
unexpected additional lesion, followed by US-guided biopsy. 
The radioactivity in the biopsy specimen was measured to 
prove that the lesion found on targeted US corresponded to 
the additional lesion found with MBI. In case of additional 
BI-RADS 4b,c or 5 lesions on MBI that remained occult on 
targeted US, MBI-guided biopsy was performed, but only if 
clinically relevant. BI-RADS 4a MBI abnormalities where 
considered benign if no correlate was found at targeted US.
Statistical analysis
The χ2 test was used to analyze significant differences 
between dense and non-dense index lesion tumor as well 
as high-grade and low-grade. A p value of <  0.05 was con-
sidered statistically significant. Statistical analysis was per-
formed using MedCalc Statistical Software version 15.11.4.
Based on T stage migration (upstaging) after MBI, the 
percentage of patients in who surgical management was 
adjusted based on the MBI results was calculated. Based 
on the biopsy-or excision-acquired pathological findings, all 
additional lesions with malignant histopathology like inva-
sive tumor and ductal carcinoma in situ (DCIS) were consid-
ered true positive, while all additional lesions with benign 
histopathology were defined false positive. On the basis of 
the detected additional lesions on MBI, the lesion-based 
positive predictive value (PPV) was calculated using the 
formula True-positive/True-positive + False Positive  ×  100.
Results
Records of 304 women with proven invasive breast cancer 
scheduled for BCS who underwent MBI between March 
2012 and December 2014 were reviewed. Seventeen of 
these women, who had additional MBI-detected lesions 
without histopathological diagnosis, were excluded from 
the final analysis. In more detail, in 4 of these 17 patients 
the multidisciplinary team agreed upon that it was not nec-
essary to prove the malignant nature of the lesion, because 
it was located nearby the index lesion and would not alter 
the treatment plan. Since these patients were treated with 
neoadjuvant therapy, it was not possible to verify the nature 
of the additional lesion afterwards. Thirteen of 17 patients 
had focal MBI lesions classified as BI-RADS 4a, meaning 
Table 1  Title: Patient characteristics
*No significant difference between dense (c, d) and non-dense (a, b) 
breast tissue (p = 0.8)
**Significant difference between high-grade (grade 3) and low-grade 
(grade 1, 2) breast tumors (p < 0.008)
a almost entirely fat; bscattered fibroglandular density; cheterogene-
ously dense; dextremely dense; IDCinvasive ductal carcinoma; ILCin-
vasive lobular carcinoma; DCISductal carcinoma in  situ; ERestrogen 
receptor; HER2human epidermal growth factor receptor 2
Number of pts 287









Mean tumor size (range) 18 mm (3–55 mm)
Multifocal/multicentric 18
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that there was doubt about the real nature of the MBI find-
ing, for example because it was visible in only one view and 
could be caused by over-projection or an artifact. In these 
13 patients, the finding was considered benign because no 
correlate was found with targeted US. The remaining 287 
patients who fulfilled the inclusion criteria were enrolled in 
this retrospective study. The characteristics of the patients 
are reported in Table 1. The mean age of the patients was 
60 years (range, 30–88 years). A significant difference was 
found between high-grade and low-grade breast tumors 
(p <  0.008), since more patients had low-grade tumors 
(grade 1 or 2). No significant difference was found between 
dense and non-dense breast tissue (p = 0.8) in this study pop-
ulation. The mean morphological maximum tumor diameter, 
obtained with MG and US, was 18 mm (range, 3–55 mm). 
In 246 patients (86%), the index lesion concerned invasive 
ductal carcinoma (IDC), in 24 patients (8%) invasive lobu-
lar carcinoma (ILC), and in 1 patient (0.3%) mixed IDC 
and ILC. The remaining 16 patients (5.7%) had other tumor 
types including 6 mucinous carcinomas, 3 papillary carci-
nomas, 3 apocrine carcinomas, 2 medullary carcinomas, and 
2 tubular carcinomas.
Concerning the diameter of the index lesion, concord-
ance between MBI and radiologic imaging was found in 261 
patients (91%). In 26 out of 287 patients (9%), MBI showed 
T stage migration with adjustment of the surgical manage-
ment in 14 of these 26 patients (54%) (Table 2). Five patients 
underwent unilateral mastectomy, 1 patient bilateral mas-
tectomy, another 5 patients were treated with large lumpec-
tomy, 2 patients received NAC before BCS, and 1 patient 
underwent quadrantectomy. In 10 of these 14 patients, the 
larger tumor extent on MBI was related to histopathologi-
cally proven DCIS around the invasive lesion (Fig. 1).
In 17 of 287 patients (6%), MBI revealed 21 proven addi-
tional lesions in the ipsilateral breast, contralateral breast 
or both breasts (Table 3). The median size of these lesions 
on MBI was 10 mm (range: 7–35 mm). Histopathological 
features were obtained by needle-biopsy from 16 out of 
Table 2  T stage migration and 
treatment adjustment following 
MBI
N number, Pts patients, MBI molecular breast imaging, BCS breast-conserving surgery, NAC neoadjuvant 
chemotherapy
N of pts Morphologi-
cal size (mm)
MBI size (mm) T stage migration Treatment 
plan before 
MBI
Treatment plan after MBI
1 20 24 T1  >  T2 BCS BCS
2 20 24 T1  >  T2 BCS BCS
3 16 35 T1  >  T2 BCS Large BCS
4 17 30 T1  >  T2 BCS BCS
5 11 35 T1  >  T2 BCS Large BCS
6 50 55 T2  >  T3 NAC + BCS NAC + BCS
7 40 63 T2  >  T3 NAC + BCS NAC + BCS
8 19 40 T1  >  T2 BCS Large BCS
9 20 27 T1  >  T2 BCS Mastectomy
10 19 30 T1  >  T2 BCS Large BCS
11 17 30 T1  >  T2 BCS Large BCS
12 20 42 T1  >  T2 BCS NAC + BCS
13 10 85 T1  >  T3 BCS Mastectomy
14 23 26 T1  >  T2 Left BCS Mastectomy
13 80 T1  >  T3 Right BCS Mastectomy
15 15 21 T1  >  T2 BCS BCS
16 20 32 T1  >  T2 BCS BCS
17 20 24 T1  >  T2 BCS BCS
18 10 26 T1  >  T2 BCS BCS
19 7 30 T1  >  T2 BCS Mastectomy
20 20 25 T1  >  T2 BCS BCS
21 40 120 T2  >  T3 BCS NAC + BCS
22 40 90 T2  >  T3 BCS Quadrantectomy
23 40 90 T2  >  T3 BCS Mastectomy
24 19 23 T1  >  T2 BCS BCS
25 16 23 T1  >  T2 BCS BCS
26 16 90 T1  >  T3 BCS Mastectomy
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21 lesions in 12 patients and by surgical excision from the 
other 5 lesions concerning another 5 patients. Breast needle-
biopsies were performed under guidance of US in 10/12 
patients and under MBI guidance in 2/12 patients. In 15 out 
of these 17 patients (88%) the 18 additional lesions turned 
out to be malignant. In 13 of these 15 patients, the malignant 
lesions concerned ipsilateral tumors (15/18 lesions) and in 2 
patients bilateral tumors (3/18 lesions) (Fig. 2). The surgi-
cal management was adjusted in 12 out of these 15 patients 
(80%). In more detail, 3 patients were converted to NAC and 
mastectomy, while 7 patients underwent ipsilateral mastec-
tomy instead of BCS, 1 patient was treated with bilateral 
mastectomy, and 1 patient with bilateral BCS. From the 18 
additional proven malignant lesions (true positives) on MBI, 
6 lesions were smaller than 10 mm (range: 6-8 mm). The 
pathologic findings of the 18 tumors included 10 IDC, 3 
ILC, and 5 DCIS. The remaining 3 additionally detected 
lesions on MBI were benign lesions (false positives) reveal-
ing mastopathy in one, one with fibroadenoma, and one 
with a mixed pattern of mastopathy and adenosis. The MBI 
lesion-related PPV was 86%.
Overall, MBI showed an unexpected larger tumor extent, 
additional tumor foci or both in 40 of 287 included patients 
(14%). In one of these 40 patients, MBI revealed both a 
larger index tumor as well as multicentricity (patient nº19 in 
Table 2 and n°10 in Table 3). In 4 of these 40 patients (10%), 
the index lesion concerned ILC. Twenty patients (50%) had 
non-dense breast tissue with breast composition a in 4 and 
breast composition b in 16 patients. Owing to the use of 
MBI, the overall treatment was adjusted in 25 patients (9%) 
(Fig. 3).
Discussion
In the present study, we evaluated the clinical impact of 
99mTc-sestamibi MBI, incorporated in the diagnostic work-
up of patients with newly diagnosed breast cancer sched-
uled for BCS, as an adjunct modality to MG and US. Based 
on our data, the preoperative use of MBI in this specific 
patient population resulted in the detection of a significantly 
larger disease extent, additional tumor foci or both in 14% of 
patients, albeit 50% of these patients had non-dense breast 
tissue on MG and only 10% had lobular type of carcinoma. 
The unexpected MBI findings led to treatment adjustment 
in 9% of all patients.
Evaluation of the extent of the index lesion using MBI 
showed a change of the local stage in 26 patients (9%) and 
local excision was abandoned in 14 of these patients. In our 
series, a larger disease extent as detected on MBI was mainly 
due to the visualization of DCIS located around the invasive 
tumor, which is in concordance with the findings of Spanu 
et al. [20]. Interestingly, in the majority of these patients no 
calcifications were found in the DCIS area on MG. Although 
it is not possible to distinguish carcinoma in situ from inva-
sive tumor based on the 99mTc-sestamibi uptake pattern, the 
total area of pathological 99mTc-sestamibi uptake guided 
our surgeons during the surgical procedure, increasing the 
rate of complete surgical treatment and avoiding additional 
surgeries. Therefore, we postulate that MBI offers the pos-
sibility to plan resection of the index lesion more accurately 
based on the extension of 99mTc-sestamibi uptake.
Additional lesions were visualized on MBI in 17 women 
(6%). Two of these patients underwent MBI-guided biopsy 
since the additional lesions remained occult even after 
targeted US. MBI-guided biopsy is a biopsy modality 
approved by the U.S. Food and Drug Administration (FDA) 
in 2009. This tool is based on stereotactic localization of the 
Fig. 1  A 52-year-old woman (patient 13, Table  2) with invasive 
breast cancer. a Right craniocaudal mammographic image and b 
right mediolateral oblique mammographic image showing a breast 
mass of 10 mm with new calcifications in the lower inner quadrant of 
the right breast, best visible on the mediolateral oblique view (white 
arrow). c Right craniocaudal and d right mediolateral oblique MBI 
images showing a large and heterogenous area of pathological uptake 
(85  mm) in the lower inner quadrant of the right breast. The treat-
ment changed from lumpectomy to mastectomy. Pathological find-
ings revealed intracystic papillary adenocarcinoma and extralesional 
ductal carcinoma in situ with extension towards the nipple
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99mTc-sestamibi avid lesion [21, 22] and is currently used 
in our clinical work-up [23]. In our series, MBI-detected 
lesions corresponded to additional proven tumors in 15 
women (5% overall detection rate). This is in line with the 
results reported in previous studies in the literature [20, 
24–29]. Lesion-related analysis demonstrated that 18 out 
of 21 additional lesions visualized on MBI resulted in true 
cancer. The high PPV of 86% suggests that a positive MBI 
scan is highly predictive for occult tumor. This is in concord-
ance with the relative high specificity of this technique as 
described in the literature [30]. A possible explanation is the 
highly specific uptake of 99mTc-sestamibi by tumor cells as 
compared to the surrounding breast tissue [12–14]. Moreo-
ver, MBI detected 6 subcentimeter additional cancers in our 
series. This agrees with prior studies [20, 27, 28] report-
ing the ability of MBI to identify occult tumors smaller 
than 1 cm. Recently, new MBI systems based on dual-head 
cadmium-zinc-telluride (CZT) detectors have been intro-
duced offering improved sensitivity for detection of small 
tumors [11]. In our series the detection of additional tumors 
on MBI has led to the abandonment of lumpectomy in 11 
women. Combining the contribution of MBI in relation to 
investigating disease extent and presence of multifocal and 
multicentric disease, the overall management was adjusted 
in 9% of all patients with newly diagnosed BC scheduled for 
lumpectomy. Additionally, MBI showed a low false-positive 
rate, thus avoiding unnecessary biopsies, complementary 
imaging, and patient anxiety.
Fig. 2  A 71-year-old woman (patient 1, Table 3) with invasive ductal 
carcinoma of the right breast and two additional tumor foci (1 in ipsi-
lateral breast and 1 in contralateral breast). a Right craniocaudal and 
b right mediolateral oblique mammographic images showing a mass 
of 9 mm in the lower inner quadrant of the breast (white arrows). c 
Right craniocaudal MBI image showing two foci with pathological 
99mTc-sestamibi uptake (arrows), one intense accumulation medially 
corresponding to the mass seen on mammography and a mild accu-
mulation laterally corresponding to the new 8-mm lesion located in 
the upper outer quadrant (multicentric lesion). d Left craniocaudal 
MBI image shows a new mild focal accumulation in the upper outer 
quadrant (arrow). e Right mediolateral oblique MBI image shows 
two intense foci (arrows): a caudal accumulation corresponding to 
the mass seen on mammography and a cranial accumulation (8 mm) 
corresponding to the new lesion located in the upper outer quadrant 
(multicentric lesion). f Left mediolateral oblique MBI image show-
ing a focal intense accumulation of 7  mm in the upper outer quad-
rant (contralateral lesion). For both additional lesions, the patient 
underwent US-guided biopsy after targeted US that revealed invasive 
ductal carcinoma in the additional lesion in the right breast and ductal 
carcinoma in situ in the additional lesion in the left breast. The treat-
ment changed from local excision (right breast) to bilateral mastec-
tomy
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In the light of our results, MBI could be a valid adjunct 
modality to MG and US for detecting both the extent of 
index lesions and additional tumor foci. Presently, MRI 
is widely used in the clinical work-up of newly diagnosed 
breast cancer in women. Although MRI shows high sensitiv-
ity, its low specificity and high costs limit a wide applica-
tion of this modality. Additionally, MRI is not applicable in 
patients with claustrophobia, overweight, implanted devices 
and renal insufficiency [31]. MBI has the potential to over-
come these limitations becoming a useful tool for almost all 
newly diagnosed breast cancer patients. Additionally, MBI 
is easy to perform and is associated with low costs. On the 
other hand, MBI requires the intravenous injection of a radi-
otracer, like 99mTc-sestamibi, which means radiation expo-
sure for the patient. However, one should keep in mind that 
the administered dose of 99mTc-labeled sestamibi for MBI 
is similar to the dose used for other commonly applied diag-
nostic functional imaging examinations such as bone scintig-
raphy and myocardial perfusion imaging [32, 33]. Moreover, 
recent technological advances in MBI allow a significant 
reduction of the injected dose of the radiopharmaceutical. 
Indeed, it is possible to use a low-dose imaging protocol 
with CZT-based dual-head MBI (150–300 MBq) [11, 17] 
as well as with NaI-based single-head MBI (260–500 MBq) 
[15, 16]. An administered dose of 150 MBq 99mTc-sestamibi 
leads to a significant reduction of absorbed dose to the breast 
(0.25 mGy) and effective dose (1.1 mSv) [18].
Finally, it is necessary to address the principal limitations 
of the present study. First, it concerns a retrospective study 
based on data collected in a single institution. Second, we 
retrospectively excluded a relative large amount of patients 
with positive MBI studies due to missing histopathologi-
cal data. This represents a potential bias of the presented 
MBI results. However, the excluded cases represented either 
patients in who the unexpected detection of additional 
lesions was not clinically relevant (in the sense that it would 
not have altered the treatment plan), or patients with a rela-
tively low probability of having additional malignant foci 
(BI-RADS 4a abnormalities without correlate at targeted 
US). Third, an injection dose of 600 MBq was applied using 
a single-head detector. Since others have found comparable 
results using low-dose protocols (260–500 MBq for single-
head MBI or 150–300 MBq for dual-head MBI) versus high-
dose protocols [15–17], it would be worthwhile to investi-
gate the performance of the low-dose protocol in the studied 
patient population, since it could lead to a significantly lower 
radiation exposure. On the other hand, the strength of this 
study is that it represents the first series evaluating the addi-
tional clinical value of MBI in a large population of patients 
Fig. 3  Flowchart showing the impact of preoperative MBI in the study population. *One patient had both T stage migration as well as an addi-
tional malignant lesion on MBI
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with proven invasive breast cancer scheduled for breast-
conserving surgery.
Conclusion
The results of the present study support that MBI is a useful 
imaging modality, which reveals a high rate of multifocal or 
multicentric lesions and bilateral disease not visualized by 
mammography and ultrasound. Additionally, MBI may play 
an important role in accurate delineation of the tumor extent 
during preoperative planning. Therefore, the incorporation 
of this modality to the clinical work-up may lead to better 
selection of patients who might benefit of BCS. However, 
larger and prospective studies, preferably using low-dose 
MBI protocols, are needed to confirm these findings.
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